中国医院用药评价与分析
中國醫院用藥評價與分析
중국의원용약평개여분석
Evaluation and Analysis of Drug-Use in Hospitals of China
2015年
8期
1004-1006
,共3页
布地奈德%特布他林%雾化吸入%慢性阻塞性肺病急性加重期%临床疗效
佈地奈德%特佈他林%霧化吸入%慢性阻塞性肺病急性加重期%臨床療效
포지내덕%특포타림%무화흡입%만성조새성폐병급성가중기%림상료효
Budesonide%Terbutaline%Atomization inhalation%Acute exacerbation of chronic obstructive pulmonary disease%Clinical efficacy
目的:探讨布地奈德联合特布他林压缩雾化吸入治疗慢性阻塞性肺疾病急性加重期的临床疗效. 方法:选择2012 年7月-2014年12月收治的慢性阻塞性肺病急性加重期患者116例,按随机数字表法分为观察组和对照组各58例,对照组患者采用内科常规治疗方法,观察组患者在对照组基础上采用布地奈德联合特布他林雾化吸入治疗. 比较2组患者的治疗效果、血气分析指标、肺功能及呼吸困难评分情况. 结果:观察组患者治疗有效率为94. 83%,明显高于对照组的81. 03%,差异有统计学意义(P<0. 05);与治疗前比较,观察组患者治疗后第一秒用力呼气量、第一秒用力呼气量/预计值、第一秒用力呼气量/用力肺活量、动脉氧分压和动脉血二氧化碳分压以及呼吸困难评分明显改善,差异有统计学意义( P<0. 05 );与对照组治疗后比较,观察组患者各指标改善程度明显,差异有统计学意义(P<0. 05). 结论:布地奈德联合特布他林压缩雾化吸入可明显改善慢性阻塞性肺病急性加重期患者呼吸困难、缺氧等症状,改善肺功能,疗效较好,值得临床推广.
目的:探討佈地奈德聯閤特佈他林壓縮霧化吸入治療慢性阻塞性肺疾病急性加重期的臨床療效. 方法:選擇2012 年7月-2014年12月收治的慢性阻塞性肺病急性加重期患者116例,按隨機數字錶法分為觀察組和對照組各58例,對照組患者採用內科常規治療方法,觀察組患者在對照組基礎上採用佈地奈德聯閤特佈他林霧化吸入治療. 比較2組患者的治療效果、血氣分析指標、肺功能及呼吸睏難評分情況. 結果:觀察組患者治療有效率為94. 83%,明顯高于對照組的81. 03%,差異有統計學意義(P<0. 05);與治療前比較,觀察組患者治療後第一秒用力呼氣量、第一秒用力呼氣量/預計值、第一秒用力呼氣量/用力肺活量、動脈氧分壓和動脈血二氧化碳分壓以及呼吸睏難評分明顯改善,差異有統計學意義( P<0. 05 );與對照組治療後比較,觀察組患者各指標改善程度明顯,差異有統計學意義(P<0. 05). 結論:佈地奈德聯閤特佈他林壓縮霧化吸入可明顯改善慢性阻塞性肺病急性加重期患者呼吸睏難、缺氧等癥狀,改善肺功能,療效較好,值得臨床推廣.
목적:탐토포지내덕연합특포타림압축무화흡입치료만성조새성폐질병급성가중기적림상료효. 방법:선택2012 년7월-2014년12월수치적만성조새성폐병급성가중기환자116례,안수궤수자표법분위관찰조화대조조각58례,대조조환자채용내과상규치료방법,관찰조환자재대조조기출상채용포지내덕연합특포타림무화흡입치료. 비교2조환자적치료효과、혈기분석지표、폐공능급호흡곤난평분정황. 결과:관찰조환자치료유효솔위94. 83%,명현고우대조조적81. 03%,차이유통계학의의(P<0. 05);여치료전비교,관찰조환자치료후제일초용력호기량、제일초용력호기량/예계치、제일초용력호기량/용력폐활량、동맥양분압화동맥혈이양화탄분압이급호흡곤난평분명현개선,차이유통계학의의( P<0. 05 );여대조조치료후비교,관찰조환자각지표개선정도명현,차이유통계학의의(P<0. 05). 결론:포지내덕연합특포타림압축무화흡입가명현개선만성조새성폐병급성가중기환자호흡곤난、결양등증상,개선폐공능,료효교호,치득림상추엄.
OBJECTIVE:To investigate the clinical efficacy of budesonide combined with terbutaline in compressing atomized inhalation in treatment of acute exacerbation of chronic obstructive pulmonary disease(AECOPD). METHODS:116 cases with AECOPD from Jul. 2012 to Dec. 2014 were divided into observation group and control group according to random number table, with 58 cases in each group. The control group received conventional treatment of internal medicine, and based on the control group, the observation group additionally received budesonide combined with terbutaline in compressing atomized inhalation. The therapeutic efficacy, blood gas analysis index, pulmonary function and dyspnea score before and after treatment between two groups were compared. RESULTS: The effective rate of observation treatment group was 94. 83%, which was significantly higher than that of the control group 81. 03%, the difference was statistically significant (P<0. 05). FEV1, FEV1/predicated value, FEV1/FVC, PAO2, PACO2 and dyspnea score in the observation group after treatment improved more obviously than before treatment, and compared with the control group after treatment, the observation group improved the indexes more obvious, the difference was statistically significant ( P < 0. 05 ). CONCLUSIONS:Budesonide combined with terbutaline in compressing atomized inhalation in treatment of AECOPD can significantly improve symptoms of dyspnea, relieve the symptoms of hypoxia, improve pulmonary function, with a satisfactory clinical efficacy. It is worthy of clinical application.
